ECCO 2020 Archives - Medical Conferences

Home > Gastroenterology > ECCO 2020

European Crohn's and Colitis Organisation 12-15 February 2020 Vienna, Austria

Letter from the Editor

Editor

Dr M. Duijvestein, UMC Amsterdam

ECCO 2020 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Gut Microbiome as Treatment Target

Response to faecal microbiota transplantation in UC

Presented By

Dr M. Quraishi, University Hospital Birmingham, UK; Dr L. Gogokhia, Weill Cornell Medicine, New York, USA

Impact of biologicals on faecal microbiota

Presented By

C. Caenepeel, KU Leuven, Belgium

Bioactives produced by gut bacteria to modulate immune response

Presented By

R. Giri, University of Queensland, Australia

Big Data Analysis

Multi-omics help describe CD phenotypes

Presented By

Dr B. Verstockt, University Hospital Leuven, Belgium

The positive impact of genetic data on drug development

Presented By

Prof. S. Vermeire, University Hospital Leuven, Belgium

Experimental Therapies: Study Results

Pipeline of IBD drugs

Presented By

Prof. W. Sandborn, University of California San Diego, USA

AMT-101: an oral human IL-10 fusion protein

Presented By

Dr R. Mrsny, Applied Molecular Transport, USA

Phase 2 results of first-in-class TL1A inhibitor

Presented By

Dr S. Danese, Humanitas University, Italy

Open-label extension study of risankizumab: final results

Presented By

Dr M. Ferrante, University Hospitals Leuven, Belgium

Clinical remission after dose escalation of upadacitinib

Presented By

Dr W. Sandborn & Dr S. Vermeire

Possible new treatment targets in IBD

Short- and Long-Term Treatment Results

Infliximab discontinuation increases relapse risk

Presented By

Kobayashi T, Kitasato University, Japan

Tofacitinib ‘real-world’ effectiveness in active UC

Presented By

Dr M. Chaparro , Hospital Universitario de La Princesa, Spain

Ustekinumab in CD: a T2T trial

Presented By

Prof. L. Peyrin-Biroulet, CHRU de Nancy, France

Subcutaneous ustekinumab as maintenance therapy in UC

Presented By

Dr R. Panaccione & Dr W.J. Sandborn

Subcutaneous vedolizumab maintenance therapy in CD

Presented By

Prof. S. Vermeire, University Hospital Leuven, Belgium

Vedolizumab treatment persistence and safety

Presented By

Dr S. Danese & Dr N.A. Cohen, Humanitas University, Milan, Italy

Specific Therapeutic Strategies

On the cutting edge of pathology and surgery

Presented By

Prof. P. B. Nunes & Prof. A. Spinelli

Impact of strategies on intestinal resection rate

Presented By

Dr D. Ley, University of Wisconsin–Madison, USA

Early ileocaecal resection in CD patients failing conventional treatment

Presented By

Dr T. Stevens, Amsterdam UMC, the Netherlands

Biologics before surgery in IBD do not elevate infection risk

Presented By

Dr S. Holubar, Cleveland Clinic, USA

Top-down infliximab superior to step-up in children with CD

Presented By

Dr M. Jongsma, Erasmus MC, the Netherlands

High versus standard adalimumab in active UC

Presented By

Prof. J. Colombel, Icahn School of Medicine at Mount Sinai, USA

Head-to-Head Comparison of Treatments

Effects of vedolizumab versus adalimumab on QoL

Presented By

Dr E.V. Loftus, Mayo Clinic, USA

Vedolizumab and anti-TNF therapies: a real-world comparison

Presented By

Dr G. Mantzaris , Evangelismos Hospital, Greece

Vedolizumab, adalimumab, and golimumab compared

Presented By

Dr F.S. Macaluso & Dr A. Casanotti

Vedolizumab versus ustekinumab

Presented By

Dr H. Alric & Dr V. Biemans

Cancer Risk

Increased risk of small bowel cancer in IBD

Presented By

Dr J. Axelrad, New York University School of Medicine, New York, USA

Increased incidence of colorectal cancer and death in CD

Presented By

Dr O. Olen, Karolinska Insitutet, Solna, Sweden

Risk of rectal, anal cancer increased in perianal CD

Presented By

Dr M.D. Wewer, University of Copenhagen, Copenhagen, Denmark

Glyco-fingerprint as risk factor of UC-associated cancer

Presented By

Dr A. Dias, Newham University Hospital, London, United Kingdom

Miscellaneous Topics

Resolution of mucosal inflammation has dramatic effect

Presented By

Dr N. Plevris, Western General Hospital, Edinburgh, UK

PICaSSO validated in real-life study

Presented By

Dr M. Iacucci, University of Birmingham, Birmingham, United Kingdom

Re-inducing inflammation in organoids from UC patients

Presented By

Dr K. Arnauts, Catholic University of Leuven, Belgium

Role of immune cells in intestinal fibrosis

Presented By

Dr B. Creyns, Catholic University Leuven, Leuven, Belgium

Association between meat consumption and IBD risk

Presented By

Dr C. Dong, Peking University, Beijing, China

CD exclusion diet corrects dysbiosis

Presented By

Dr J. van Limbergen , Amsterdam University, The Netherlands

Table of Contents

Featured articles

Gut Microbiome as Treatment Target

Big Data Analysis

Experimental Therapies: Study Results

Short- and Long-Term Treatment Results

Specific Therapeutic Strategies

Head-to-Head Comparison of Treatments

Cancer Risk

Miscellaneous Topics